Study M984
Study name | Lee S 2022 |
Title | Discovery and validation of acetyl-L-carnitine in serum for diagnosis of major depressive disorder and remission status through metabolomic approach |
Overall design | The aim of this study was to discover and validate biomarkers for the diagnosis of depression in consideration of exposure to drug treatment including antidepressants that contribute to the heterogeneity of the major depressive disorder (MDD) subgroup. The MDD patient group (MDD group) comprising the discovery and validation sets consisted of 76 drug-treated or non-drug treated patients. The control group comprised 61 participants (control group). The presence of different metabolites between the two groups was confirmed through serum metabolite profiling between the MDD group and the control group. |
Study Type | Type1; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | Not reported |
Sample size | 137 |
Tissue | Peripheral; Blood; Serum; |
Platform | MS-based; LC-MS: Agilent 1290 Infinity II liquid chromatography system with Agilent 6546 quadrupole time-of-flight (Q-TOF) system (Agilent Technologies, Santa Clara, CA, USA); |
PMID | |
DOI | |
Citation | Lee S, Mun S, Lee YR, et al. Discovery and validation of acetyl-L-carnitine in serum for diagnosis of major depressive disorder and remission status through metabolomic approach. Front Psychiatry 2022;13:1002828. |
Metabolite |
